Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β

BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. RESULTS: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acet...

Descripción completa

Detalles Bibliográficos
Autores principales: Simpson-Yap, Steve, Pirmani, Ashkan, De Brouwer, Edward, Peeters, Liesbet M., Geys, Lotte, Parciak, Tina, Helme, Anne, Hillert, Jan, Moreau, Yves, Edan, Gilles, Spelman, Tim, Sharmin, Sifat, McBurney, Robert, Schmidt, Hollie, Bergmann, Arnfin, Braune, Stefan, Stahmann, Alexander, Middleton, Rodden, Salter, Amber, Bebo, Bruce, van der Walt, Anneke, Butzkueven, Helmut, Ozakbas, Serkan, Karabudak, Rana, Boz, Cavit, Alroughani, Raed, Rojas, Juan I, van der Mei, Ingrid, Sciascia do Olival, Guilherme, Magyari, Melinda, Alonso, Ricardo, Nicholas, Richard, Chertcoff, Anibal, Zabalza, Ana, Arrambide, Georgina, Nag, Nupur, Descamps, Annabel, Costers, Lars, Dobson, Ruth, Miller, Aleisha, Rodrigues, Paulo, Prčkovska, Vesna, Comi, Giancarlo, Kalincik, Tomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310378/
https://www.ncbi.nlm.nih.gov/pubmed/35917745
http://dx.doi.org/10.1016/j.msard.2022.104072
Descripción
Sumario:BACKGROUND: Interferon-β, a disease-modifying therapy (DMT) for MS, may be associated with less severe COVID-19 in people with MS. RESULTS: Among 5,568 patients (83.4% confirmed COVID-19), interferon-treated patients had lower risk of severe COVID-19 compared to untreated, but not to glatiramer-acetate, dimethyl-fumarate, or pooled other DMTs. CONCLUSIONS: In comparison to other DMTs, we did not find evidence of protective effects of interferon-β on the severity of COVID-19, though compared to the untreated, the course of COVID19 was milder among those on interferon-β. This study does not support the use of interferon-β as a treatment to reduce COVID-19 severity in MS.

Ejemplares similares